Convertible Loan Notes

Hemogenyx Pharmaceuticals secured £620,000 through convertible loan notes (CLNs) to fund the clinical trial of HG-CT-1, a CAR-T cell therapy. Issued at £5.30 per share, the non-interest bearing CLNs will automatically convert into 116,982 Ordinary Shares around November 15, 2025, following eased headroom restrictions under FCA Prospectus Rules. The funding supports the ongoing Phase I trial for relapsed or refractory acute myeloid leukemia. The new shares will be admitted to trading on the London Stock Exchange.